Medicinal Chemistry Services
Chemistry-Led Molecular Design for Confident Discovery Decisions
PI Health Sciences provides integrated medicinal chemistry services at the core of our drug discovery chemistry platform — translating biological hypotheses into rational, optimized small molecules. Our medicinal chemists design, synthesize, and refine chemical matter across hit identification, hit-to-lead optimization, and early lead development, with an emphasis on chemical robustness, biological relevance, and data-driven decision confidence.
Whether you are advancing a phenotypic hit, a fragment, or a screening output, our medicinal chemistry CRO team delivers structured, science-led programs built around your discovery goals.
Our Medicinal Chemistry Service Capabilities
01
Hit Identification and Early Chemistry Support
We provide chemistry support for hit identification programs, including the synthesis and evaluation of hit compounds, initial structure–activity relationship (SAR) exploration, and assessment of early chemical series. These activities help establish initial structure–activity trends, identify opportunities for molecular refinement, and support evidence-based decisions on which compounds to advance.
02
Hit-to-Lead Optimization
Our hit-to-lead optimization programs use iterative design–synthesis–evaluation cycles to improve the quality of promising chemical series. By assessing potency, selectivity, and physicochemical properties alongside available biological and ADME data, we help refine compounds and prioritize leads for further development.
03
Medicinal Chemistry Design and SAR Development
Our medicinal chemistry teams apply rational molecular design and systematic SAR development to understand how structural modifications influence biological activity and molecular properties. These insights guide compound selection, inform subsequent design cycles, and support the development of more promising candidates.
04
Scaffold Identification and Optimization
We support the identification, exploration, and optimization of molecular scaffolds to establish productive starting points for drug discovery. By evaluating structural diversity, chemical stability, and structure–property relationships, we help identify opportunities to improve compound performance and establish viable optimization pathways.
05
Synthetic Route Design and Feasibility Assessment
Synthetic route design and feasibility assessment help determine whether proposed molecular modifications can be translated into practical, reproducible chemistry. We evaluate route complexity, synthetic accessibility, step efficiency, and potential chemical or impurity-related challenges to inform compound design and reduce avoidable synthetic bottlenecks.
06
Knowledge-Driven Handoff to Preclinical Chemistry
We support the transition from early discovery chemistry to subsequent development activities through structured documentation of compound design rationale, SAR findings, synthetic routes, and relevant chemical characterization. This knowledge transfer helps preserve critical program insights and supports continuity as promising compounds progress toward preclinical evaluation.
How Our Medicinal Chemistry Approach Is Different
Our medicinal chemistry services are designed around scientific hypotheses, compound quality, and informed discovery decisions rather than synthesis throughput alone. Each proposed structural modification is evaluated against the available biological evidence, chemical properties, and synthetic feasibility before the next design–synthesis cycle is prioritized.
We work as an integrated discovery partner, collaborating across medicinal chemistry, biology, DMPK, and computational chemistry. This cross-functional approach connects molecular design with biological response and available ADME data, helping teams interpret SAR findings and make more informed decisions about compound progression.
Our Medicinal Chemistry Services focus on:
- Molecular design guided by SAR trends and biological feedback
- Strategic scaffold selection, expansion, and refinement
- Optimization of potency, selectivity, and physicochemical properties
- Early identification and mitigation of chemical liabilities
- Synthetic feasibility assessed from the earliest design cycles
- Prioritization of chemical series with sustainable optimization pathways
PI Health Sciences brings together chemistry-led design and cross-functional scientific insights to help discovery teams prioritize promising compounds and progress programs with greater confidence.
Why Partner with PI Health Sciences for Medicinal Chemistry Services
Integrated Discovery Platform
Medicinal chemistry seamlessly integrated with biology, DMPK, and in-silico teams to enable chemistry-led, data-driven discovery decisions.
Experienced Scientific Teams
Proven expertise in small-molecule design, SAR development, and hit-to-lead optimization across diverse therapeutic areas.
Faster Decision-Making
Iterative design–synthesis–data cycles enabling rapid convergence on viable chemical series and confident go/no-go decisions.
Risk Mitigation
Early identification of chemical liabilities, developability risks, and synthetic challenges to minimize late-stage failures.
Flexible Engagement Models
FTE, milestone-based, or fully integrated program support tailored to hit identification and hit-to-lead chemistry needs.
Frequently asked questions
We’re here to help with any questions you have about our plans, supported features, and how our model works.
What are medicinal chemistry services in drug discovery?
Medicinal chemistry services focus on the design, synthesis, and optimization of small molecules to improve potency, selectivity, and drug-like properties. At PI Health Sciences, these services are integrated with biology and DMPK to accelerate hit identification and hit-to-lead programs.
How does medicinal chemistry support hit-to-lead optimization?
Medicinal chemistry enables iterative optimization of hit compounds through SAR-driven design, improving potency, selectivity, and ADME properties. This ensures faster progression from hit to viable lead candidates with reduced risk.
What makes PI Health Sciences’ medicinal chemistry approach different?
Our approach is chemistry-led and decision-centric, integrating biology, DMPK, and computational insights. We focus on quality chemical matter and early decision-making, not just compound volume, enabling faster and more confident discovery outcomes.
What is SAR (Structure-Activity Relationship) in medicinal chemistry?
SAR refers to the relationship between a compound’s chemical structure and its biological activity. By systematically modifying structures, we identify trends that guide rational optimization of drug candidates.
How do you ensure early risk mitigation in medicinal chemistry programs?
We identify and address risks early by evaluating:
- Chemical liabilities
- Synthetic feasibility
- Physicochemical properties
- Developability challenges
This reduces late-stage failures and improves overall program success rates.